YARW · Yarrow Bioscience, Inc.

Track YARW — free

$20.00 +0.43 (+2.20%) At close · Oct 29

Rebalance outlook locked

Market Cap

$52.15M

2.67M

Volume · Oct 29 228.61K Avg daily vol (3M) 108.87K

Up next

Latest filing: 10-Q

filed Aug 13, 2026

Q3 2021 earnings call transcript

call held Nov 10, 2021

Metrics snapshot

Useful current figures from the complete screener profile.

View all 122 metrics

Revenue (TTM)

$482,000

Trailing 12 months

Net income (TTM)

−$18.71M

Trailing 12 months

Revenue growth YoY

+40.6%

Year over year

Operating margin

-4,134.6%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$22.93M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+0.4%

Year over year · more shares

Price change (1Y)

—

Trailing year

Short interest

4.9%

Latest settlement · 1.3 days to cover

View all 122 metrics

Quarterly results

Revenue Net income Net loss

▼1% $98,000 −$6.25M '24 Q1 ▲46.7% $198,000 −$9.41M '24 Q2 ▲6.1% $121,000 −$12.16M '24 Q3 ▲10.5% $84,000 −$12.02M '24 Q4* ▲106.1% $202,000 −$8.61M '25 Q1 ▼65.2% $69,000 −$5.75M '25 Q2 ▼57.4% $86,000 −$3.58M '26 Q1 LATEST ▲40.6% $97,000 −$3.01M '26 Q2

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Neutral Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 17.2 · elevated Equity put/call 0.58

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg −35%

below

Price vs 50-day avg −23%

below

RSI (14) 41

neutral

MACD trend Positive

52-week position 12%

near low

Volume (OBV) Bullish div.

accumulating

Momentum

relative strength

Very Weak

1-month return −15%

trailing

6-month return −39%

trailing

YTD return −31%

this year

Relative strength −44%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $26 › 200d $31 — 200d above 50d

Institutional flow Distributing

5 of 47 funds reported for Sep 30 · net -19.6K sh shares · +1 new

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

4.94% of float · ▼ -30.4% MoM · 1.3 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

47 holders — near 3-yr high, broad support

Squeeze score 43

elevated · 0–100

Fundamentals

Strong

EPS growth +33%

Y/Y

Free cash flow $-33.1M

Balance sheet $24.0M

net cash

Quant / Vol

risk profile

Very High

Volatility 88%

annualized · 1-yr

Max drawdown −60%

past year

ATR 8.8%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

3 · 2 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−35% Bearish

Price vs 50-day avg

−23% Bearish

RSI (14)

41 Neutral

MACD trend

Positive Bullish

52-week position

12% Bearish

Volume (OBV)

Bullish div. Bullish

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $26 › 200d $31 — 200d above 50d

Institutional flow Distributing

5 of 47 funds reported for Sep 30 · net -19.6K sh shares · +1 new

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

4.94% of float · ▼ -30.4% MoM · 1.3 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

47 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $16 Now $20 · 12% Range high $46

vs 200-day avg -35% vs 50-day avg -23%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
YARW Yarrow Bioscience, Inc. this stock	$52.15M	—	+13.8%	—	4.9%
VRTX Vertex Pharmaceuticals Inc	$136.50B	+19.1%	+46.2%	31.4	1.7%
MRNA Moderna, Inc.	$85.50B	+655.4%	+4.3%	—	8.2%
REGN Regeneron Pharmaceuticals, Inc.	$84.33B	+6.1%	+20.8%	20.3	2.1%
CSLLY Csl Ltd	$67.18B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

% held: 12.0%
Reported: 5 of 47
Top holder: ADAR1 Capital Management,…

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Falling

Shares short

132.0K

Days to cover: 1.3d
Change: -57.6K sh

View

Short Volume

Short vol %

31%

As of: Oct 29, 2026

Short Total

View

Fails to Deliver

FTD shares

327

Value: $7.8K
As of: Sep 29, 2026

View

Off-Exchange

Off-exchange %

41.7%

Week of: Sep 21, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$570.0K

Net income (FY): $-26.5M
EPS diluted: $-31.00

View

Filings

SEC Filings

Latest

8-K

Filed: Sep 14, 2026
This year: 19

View

Exempt Offerings

Offering

$88.2M

Filed: Nov 16, 2023

View

Earnings & Events

Webcasts

Last webcast

Nov 6, 2025

View

Performance

	5D	20D	120D	MTD	YTD
YARW	+2.0%	-15.3%	-39.5%	-11.2%	-31.0%
SPY	+0.7%	+0.7%	+4.3%	+0.9%	+12.8%
vs SPY	+1.3%	-16.0%	-43.8%	-12.1%	-43.9%

Key facts CIK 1566044 CUSIP 92941V407 13F (30d) 3 filings 3 filers Visit website Investor relations

YARW · Yarrow Bioscience, Inc.

Price & Indicators

Up next

Metrics snapshot

Quarterly results

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance